Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Merck
Mallinckrodt
Moodys
Harvard Business School

Last Updated: May 23, 2022

CLINICAL TRIALS PROFILE FOR ZIAGEN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ZIAGEN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004585 ↗ A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults Completed Glaxo Wellcome Phase 4 1999-10-01 The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.
NCT00004981 ↗ Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) Unknown status Glaxo Wellcome Phase 3 1969-12-31 The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.
NCT00005017 ↗ Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status Glaxo Wellcome Phase 4 1969-12-31 The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV).
NCT00038506 ↗ Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure Completed ViiV Healthcare Phase 4 2002-03-01 This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.
NCT00085943 ↗ KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks Completed GlaxoSmithKline Phase 3 2004-05-01 This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZIAGEN

Condition Name

Condition Name for ZIAGEN
Intervention Trials
HIV Infections 7
HIV 3
HIV Infection 2
Infection, Human Immunodeficiency Virus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZIAGEN
Intervention Trials
HIV Infections 10
Infections 4
Infection 4
Communicable Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZIAGEN

Trials by Country

Trials by Country for ZIAGEN
Location Trials
United States 60
Germany 4
Canada 3
Italy 3
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ZIAGEN
Location Trials
California 5
New York 5
Florida 4
Texas 4
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZIAGEN

Clinical Trial Phase

Clinical Trial Phase for ZIAGEN
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZIAGEN
Clinical Trial Phase Trials
Completed 11
Unknown status 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZIAGEN

Sponsor Name

Sponsor Name for ZIAGEN
Sponsor Trials
GlaxoSmithKline 3
Glaxo Wellcome 3
ViiV Healthcare 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZIAGEN
Sponsor Trials
Other 12
Industry 9
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Merck
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.